Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 16, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 111.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 16, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 15, 2027 | Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis | Trial Milestone | Phase 2 |
| October 15, 2027 | Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis | Trial Milestone | Phase 2 |
| October 15, 2028 | ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa | Trial Milestone | Phase 2 |
| May 15, 2030 | An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis | Trial Milestone | Phase 2 |
Track ORKA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ORKA in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 24, 2026 | 8-K filed: Leadership change | Corporate | — |
| August 20, 2026 | ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose | Trial Milestone | Phase 1 |
| August 10, 2026 | Quarterly results filed (8-K) | Earnings | — |
| June 1, 2026 | 8-K filed: Other event | Filing | — |
| April 30, 2026 | Quarterly results filed (8-K) | Earnings | — |
| April 27, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| March 25, 2026 | ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis | Trial Milestone | Phase 2 |
| March 13, 2026 | ORKA-001 in Healthy Volunteers | Trial Milestone | Phase 1 |
| December 11, 2025 | 8-K filed: Leadership change | Corporate | — |
| September 22, 2025 | 8-K filed: Material agreement, Reg FD disclosure | Corporate | — |
| July 1, 2025 | 8-K filed: Leadership change | Corporate | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.